Obesity tied to hepatitis C treatment failure (press release)

Email this article to a friend

Printable Version

Articles Related to This Article: • DHEA for weight loss: miracle drug or unproven experiment? • The link between monosodium glutamate (MSG) and obesity • Childhood Obesity Initiative Is Same Old Story: Looks Good on Paper, But Kids Keep Getting Fatter Sign the Health Revolution Petition Join the call for genuine health freedom in America. End FDA tyranny and Big Pharma corruption. Watch the video and sign the petition here.

Obese patients who are treated for chronic hepatitis C virus (HCV) infection are more likely to have a better outcome if the underlying abnormalities caused by excessive fat tissue are corrected first, according to a review published in the medical journal Hepatology.

The lead author, Dr. Michael R. Charlton of the Mayo Clinic, Rochester, Minnesota, and colleagues point out that obesity is considered to be a metabolic condition, not simply a matter of being very overweight.

Obesity in patients with HCV infection is associated inflammation and insulin resistance, a "prediabetic" abnormality of blood sugar. These patients may also have steatosis, "fatty liver disease;" progression of fibrosis, scarring of the liver; and poor response to interferon and ribavirin, the standard treatment for HCV infection.

Patients with hepatitis C and obesity-related fatty liver disease are also at greater risk for more advanced liver disease.

Weight loss to reduce fat tissue is an important first step in improving response to treatment, the investigators advise. Also important is treatment with diabetes drugs, such as metformin and pioglitazone, to improve insulin sensitivity and reduce fat accumulation in the liver. This might reverse disease progression, the researchers note.

Other approaches to enhance patients' response to combination drug therapy may include longer duration of treatment and higher doses to counteract the decreased response to the drugs. Rather than basing doses on weight, they suggest, drug doses could be based on body mass index, a ratio of height to weight.

"Treatment strategies that focus on improving underlying metabolic factors associated with poor response to combination therapy," conclude the researchers, are "more likely to overcome the low sustained viral response rates observed in obese patients infected with HCV."

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • DHEA for weight loss: miracle drug or unproven experiment? • The link between monosodium glutamate (MSG) and obesity • Childhood Obesity Initiative Is Same Old Story: Looks Good on Paper, But Kids Keep Getting Fatter	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/020014_obesity_hepatitis_C_hepatitis.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/020014_obesity_hepatitis_C_hepatitis.html">Obesity tied to hepatitis C treatment failure (press release)</a>